205 related articles for article (PubMed ID: 17311611)
21. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
22. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma.
Yamashita T; Honda M; Takatori H; Nishino R; Minato H; Takamura H; Ohta T; Kaneko S
J Hepatol; 2009 Jan; 50(1):100-10. PubMed ID: 19008011
[TBL] [Abstract][Full Text] [Related]
23. Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications.
Hui KM
Cancer Lett; 2009 Dec; 286(1):96-102. PubMed ID: 19095350
[TBL] [Abstract][Full Text] [Related]
24. Signaling networks in human hepatocarcinogenesis--novel aspects and therapeutic options.
Breuhahn K; Schirmacher P
Prog Mol Biol Transl Sci; 2010; 97():251-77. PubMed ID: 21074736
[TBL] [Abstract][Full Text] [Related]
25. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis.
Lu Y; Wu LQ; Li CS; Wang SG; Han B
Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):174-8. PubMed ID: 18397854
[TBL] [Abstract][Full Text] [Related]
26. [Hepatocellular carcinoma--epidemiology and treatment].
Małkowski P; Pacholczyk M; Łagiewska B; Adadyński L; Wasiak D; Kwiatkowski A; Chmura A; Czerwiński J
Przegl Epidemiol; 2006; 60(4):731-40. PubMed ID: 17682755
[TBL] [Abstract][Full Text] [Related]
27. [The treatment of hepatocellular carcinoma: an update].
Vero V; Racco S; Biolato M; Pompili M; Gasbarrini G; Miele L; Grieco A
Minerva Med; 2009 Jun; 100(3):173-93. PubMed ID: 19571783
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic.
Voiculescu M; Winkler RE; Moscovici M; Neuman MG
J Gastrointestin Liver Dis; 2008 Sep; 17(3):315-22. PubMed ID: 18836626
[TBL] [Abstract][Full Text] [Related]
29. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX
J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489
[TBL] [Abstract][Full Text] [Related]
30. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.
Schmitz KJ; Wohlschlaeger J; Lang H; Sotiropoulos GC; Malago M; Steveling K; Reis H; Cicinnati VR; Schmid KW; Baba HA
J Hepatol; 2008 Jan; 48(1):83-90. PubMed ID: 17998146
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
32. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
[TBL] [Abstract][Full Text] [Related]
33. Liver cancer stem cells: implications for a new therapeutic target.
Lee TK; Castilho A; Ma S; Ng IO
Liver Int; 2009 Aug; 29(7):955-65. PubMed ID: 19490415
[TBL] [Abstract][Full Text] [Related]
34. Treatment and prognosis of hepatocellular carcinoma: a population based study in France.
Borie F; Bouvier AM; Herrero A; Faivre J; Launoy G; Delafosse P; Velten M; Buemi A; Peng J; Grosclaude P; Trétarre B
J Surg Oncol; 2008 Dec; 98(7):505-9. PubMed ID: 18932235
[TBL] [Abstract][Full Text] [Related]
35. On the TRAIL to therapeutic intervention in liver disease.
Herr I; Schemmer P; Büchler MW
Hepatology; 2007 Jul; 46(1):266-74. PubMed ID: 17596886
[TBL] [Abstract][Full Text] [Related]
36. Proteomics for the early detection and treatment of hepatocellular carcinoma.
Feng JT; Shang S; Beretta L
Oncogene; 2006 Jun; 25(27):3810-7. PubMed ID: 16799622
[TBL] [Abstract][Full Text] [Related]
37. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma.
Feo F; Frau M; Tomasi ML; Brozzetti S; Pascale RM
Exp Biol Med (Maywood); 2009 Jul; 234(7):726-36. PubMed ID: 19429855
[TBL] [Abstract][Full Text] [Related]
38. Hippo signaling in oval cells and hepatocarcinogenesis.
Zheng T; Wang J; Jiang H; Liu L
Cancer Lett; 2011 Mar; 302(2):91-9. PubMed ID: 21247686
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma (HCC): current and evolving therapies.
Gish RG; Baron A
IDrugs; 2008 Mar; 11(3):198-203. PubMed ID: 18311657
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
